Outlook Therapeutics, Inc.

As of September 9, 2025, Outlook Therapeutics, Inc. shows a neutral technical trend with mixed signals, including a bearish weekly MACD and a significant 1-year return of -83.31%, underperforming the S&P 500's 17.14%.

As of August 14, 2025, Outlook Therapeutics, Inc. is rated as risky due to negative valuation ratios and poor stock performance, indicating it is overvalued compared to its peers.

As of December 23, 2020, Outlook Therapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics and significant underperformance compared to peers and the S&P 500.

As of June 9, 2025, Outlook Therapeutics, Inc. shows a mildly bearish trend due to daily moving averages, despite mixed signals from weekly and monthly indicators, with the stock down 5.08% over the past week.

As of March 2022, the management team of Outlook Therapeutics, Inc. includes Executive Chairman Randy Thurman, CEO Lawrence Kenyon, and Directors Gerd Auffarth, Julian Gangolli, Andong Huang, Yezan Haddadin, and Kurt Hilzinger. Kenyon holds multiple key executive roles, including President and CFO.

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing biosimilar therapeutics, particularly monoclonal antibodies, in immunology and oncology. It has a market cap of USD 72.42 million and reported a net profit loss of USD 46 million as of March 2025.

As of Jun 18, Outlook Therapeutics, Inc. has a market capitalization of 72.42 million and reported net sales of 0.00 million with a net profit of 21.12 million over the latest four quarters. As of Sep 24, the company has shareholder's funds of -73.08 million and total assets of 28.82 million.